Amphotericin B clinical trials
Amphotericin B is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Observational. The sponsor with the most trials is Qiu Ye (1). The most-studied condition is Mucormycosis. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Amphotericin B is approved
All regulators →Of the three regulators tracked here, the first to approve Amphotericin B was the US, on 13 Oct 1965. It is approved in 2 of the 3 regulators tracked here.
- 2 EU orphan designations, most recently for treatment of cryptococcosis (10 Aug 2022, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Amphotericin B
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Amphotericin B works
All drug targets →- AIDSPhase 3
- CandidemiaPhase 3
- Candidiasis, InvasivePhase 3
- Decreased total granulocyte countPhase 3
- FeverPhase 3
- HIV infectious diseasePhase 3
- Allergic bronchopulmonary aspergillosisPhase 3
- BlastomycosisPhase 3
- Chronic rhinosinusitisPhase 3
- Cutaneous leishmaniasisPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL267345, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Amphotericin B
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 3 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Amphotericin B
- ChEMBL
- CHEMBL267345
- DrugBank
- DB00681
- PubChem CID
- 91819969
- CAS number
- 1397-89-3
- FDA UNII
- 7XU7A7DROE
- Wikidata
- Q412223
- Wikipedia
- Amphotericin B
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Amphotericin B
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Amphotericin B for Breakthrough Fungal Infections After Triazole Prophylaxis in Hematological Patients
NCT07559032 · ClinicalTrials.gov ↗ · Invasive Fungal Disease
|
Not applicable | Not yet open | Peking University People's Hospital | China |
|
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
NCT07191756 · ClinicalTrials.gov ↗ · Mucormycosis
|
Observational | Active, closed | Qiu Ye | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Amphotericin B in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Amphotericin B. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
CombiMucor - Efficacy of combination therapy with isavuconazole and intermittent high doses liposomal amphotericin B for the treatment of mucormycosis
2025-521505-40-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 2 | Authorised | Assistance Publique Hopitaux De Paris | France |
|
A Phase 2, monocentric, prospective, nonrandomized, open-label, experimental study to evaluate efficacy and safety of intrabronchial instillation of liposomal Amphotericin B in patients with simple pulmonary aspergilloma.
2025-523501-15-00 · CTIS ↗ · Respiratory Tract Diseases
|
Phase 2 | Authorised | Pauls Stradins Clinical University Hospital | Latvia |
Amphotericin B across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
3 single-substance products containing Amphotericin B on the HPRA medicines list.
- AmBisome Liposomal Amphotericin B 50 mg Powder for Concentrate for Dispersion for InfusionGilead Sciences Ireland UC · PA2322/001/001 · Marketed
- Fungizone 50 mg Powder for sterile concentrateCHEPLAPHARM Arzneimittel GmbH · PA2239/004/001 · Marketed
- Amphotericin B Liposomal Tillomed 50 mg Powder for concentrate for dispersion for infusionTillomed Pharma GmbH · PA22720/016/001 · Not marketed
Supply shortages
No entry for Amphotericin B in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Amphotericin B
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Qiu Ye | 1 |
| Peking University People's Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Amphotericin B trials
How many clinical trials are testing Amphotericin B?
2 current trials in our China register name Amphotericin B as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Amphotericin B trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Amphotericin B clinical trials?
Qiu Ye (1) and Peking University People's Hospital (1). The number in brackets is how many trials each organisation leads.
Is Amphotericin B licensed in Ireland?
Yes. The HPRA medicines list includes 3 single-substance products containing Amphotericin B, for example AmBisome Liposomal Amphotericin B 50 mg Powder for Concentrate for Dispersion for Infusion (Gilead Sciences Ireland UC). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Amphotericin B shortage?
Not in the lists we track: Amphotericin B has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Amphotericin B works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Amphotericin B works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Amphotericin B (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.